Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Was The Gastric Volvulus Treatment Market Worth In 2025, And What Is Its Anticipated Value By 2029?
Significant expansion has been observed in the gastric volvulus treatment market size recently. Forecasts suggest an increase from $27.36 billion in 2024 to $28.86 billion in 2025, driven by a 5.5% compound annual growth rate (CAGR). Over previous periods, this growth stemmed from progress in surgical methods, better diagnostic technologies, heightened awareness and education, an increase in minimally invasive interventions, and dedicated research and clinical trials.
The gastric volvulus treatment market is anticipated to show significant expansion over the next few years. It is projected to reach $37.18 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.5%. This forecasted growth can be attributed to regulatory adjustments and new approvals, innovations in surgical procedures, a rising geriatric population, the development of customized treatment plans, and the adoption of advanced imaging techniques. Notable trends during this period include the prevalence of minimally invasive surgical techniques, greater awareness leading to early intervention, intensified research into various treatment modalities, collaborative medical practices, and patient-specific treatment approaches.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9382&type=smp
Which Drivers Are Supporting Growth Of The Gastric Volvulus Treatment Market?
The increasing demographic of older adults is projected to drive the expansion of the gastric volvulus treatment market in the future. This demographic encompasses individuals aged 65 and above. Due to diminished immunity and advancing age, the older adult population is susceptible to numerous health conditions. Specifically, gastric volvulus manifests in individuals aged over 50. Consequently, the expansion of the elderly demographic is anticipated to stimulate the market. For example, data from January 2024, released by the US-based nonprofit Population Reference Bureau (PRB), forecasts that the count of Americans aged 65 and above will rise significantly from 58 million in 2022 to 82 million by 2050, representing a 47% increase, with their share of the total population expanding from 17% to 23%. These demographic trends confirm that an increasing elderly populace is a primary driver for the gastric volvulus treatment market.
What Are The Key Segments In The Gastric Volvulus Treatment Market?
The gastric volvulus treatmentmarket covered in this report is segmented –
1) By Type: Organo-Axial Volvulus; Mesentero-Axial Volvulus
2) By Treatment Type: Medication; Surgery
3) By Route Of Administration: Oral; Parenteral
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy
5) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) By Organo-Axial Volvulus: Surgical Intervention; Endoscopic Management; Gastropexy; Other Treatment Methods
2) By Mesentero-Axial Volvulus: Surgical Intervention; Gastropexy; Endoscopic Techniques; Other Treatment Approaches
What Trends Are Redefining The Gastric Volvulus Treatment Market Dynamics?
Product innovation represents a key trend experiencing growing popularity within the gastric volvulus treatment market. Leading companies operating in this market are introducing novel products to sustain their standing in the gastric volvulus treatment market. For example, in October 2023, Pfizer Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved VELSIPITY (etrasimod). VELSIPITY (etrasimod) functions as a once-daily oral sphingosine-1-phosphate (S1P) receptor activator for individuals suffering from moderate to severe active ulcerative colitis (UC). VELSIPITY’s officially recommended dosage is 2 mg. VELSIPITY enables adults with moderately to severely active UC to attain steroid-free resolution through an oral, once-daily pill that exhibits a positive benefit-risk profile. The FDA’s approval of VELSIPITY today signifies an important turning point for UC patients who require innovative therapies for this chronic illness and are prepared to commence advanced treatment.
Who Are The Primary Competitors In The Global Gastric Volvulus Treatment Market?
Major companies operating in the gastric volvulus treatment market include PAI Pharma, Sun Pharmaceutical Industries Ltd., ANI Pharmaceuticals Inc., Fresenius SE and Co. KGaA, Mayne Pharma Group Limited, Sawai Pharmaceutical Co.Ltd., Teva Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals Ltd., Tris Pharma Inc., Pfizer Inc., Mallinckrodt Pharmaceuticals, GlaxoSmithKline plc, Endo International plc, Vintage Labs, Zydus Group, Bayer AG, AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A., Novartis International AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Sanofi S.A., Celltrion Inc., HanAll Biopharma, AstraZeneca plc
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report
What Regional Growth Trends Are Shaping The Gastric Volvulus Treatment Market Outlook?
North America was the largest region in the gastric volvulus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the gastric volvulus treatment market report during the forecast period. The regions covered in the gastric volvulus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Gastric Volvulus Treatment Market Report:
https://www.thebusinessresearchcompany.com/customise?id=9382&type=smp
Browse Through More Reports Similar to the Global Gastric Volvulus Treatment Market 2025, By The Business Research Company
Wearable Blood Pressure Monitors Global Market Report 2025
Patient Blood Management Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report
Conjugated Monoclonal Antibodie Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model